Eli Lilly and Company (NYSE: LLY) — Company Overview, News & Financial Data
Eli Lilly creates high-quality medicines across various therapeutic areas, with a focus on drug discovery and innovation in healthcare.
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical corporation engaged in the discovery, development, manufacturing, and commercialization of human healthcare products. Headquartered in Indianapolis, Indiana, the enterprise focuses primarily on therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Its product portfolio includes diabetes and obesity treatments, targeted cancer therapies, biological agents for autoimmune conditions, and neurodegenerative disease treatments. The company operates research and development centers, chemical manufacturing facilities, and biotechnology drug product plants globally, distributing its prescription medicines through wholesalers, pharmacies, and healthcare institutions across North America, Europe, Asia, and other international markets.
Snapshot
Operations
Products and/or services of Eli Lilly and Company
- Cardiometabolic Therapeutics: Development and commercialization of injectable metabolic regulators and insulin therapies, including tirzepatide formulations marketed for type 2 diabetes and chronic weight management, dulaglutide dual-acting agents, and biosynthetic insulin products distributed globally across hospital and retail pharmacy channels.
- Oncology Therapies: Production and global distribution of targeted cancer therapeutics, featuring oral cyclin-dependent kinase inhibitors like abemaciclib for breast cancer, Bruton tyrosine kinase inhibitors for hematologic malignancies, and monoclonal antibodies indicated for advanced solid tumors and gastrointestinal cancers.
- Immunology Treatments: Supply of specialized biological agents and targeted small molecules for autoimmune and inflammatory diseases, including interleukin inhibitors such as ixekizumab for psoriasis, Janus kinase inhibitors for rheumatoid arthritis, and selective antibodies for inflammatory bowel disease.
- Neuroscience Therapies: Commercialization of central nervous system pharmaceuticals and neurodegenerative disease treatments, including amyloid plaque-targeting monoclonal antibodies like donanemab for early Alzheimer disease, calcitonin gene-related peptide antagonist therapies for migraine prevention, and psychiatric medications.
- Pharmaceutical Manufacturing Facilities: Operation of biotechnology production complexes and chemical synthesis facilities across North America, Europe, and Asia, manufacturing active pharmaceutical ingredients, parenterals, pre-filled pens, auto-injectors, and sterile biologic drug products under international good manufacturing standards.
- Biopharmaceutical Pipeline Discovery: Clinical development of investigational compounds and therapeutic candidates utilizing peptide chemistry, monoclonal antibody engineering, genetic technologies, and targeted small molecules to treat rare diseases, metabolic disorders, oncology indications, and chronic neurodegenerative conditions globally.
Eli Lilly and Company executive team
- David A. RicksChairman, President & CEO
- Lucas E. MontarceExecutive VP & CFO
- Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories
- Anat HakimExecutive VP, General Counsel & Secretary
- Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development
- Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Diogo RauExecutive VP and Chief Information & Digital Officer
- Michael CzaparSenior Vice President of Investor Relations
- Eric DozierExecutive VP & Chief People Officer
- Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities
Latest news about Eli Lilly and Company
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
United StatesEli Lilly declares $1.73 fourth-quarter dividend
United StatesEli Lilly shares surge 5.45% to record high
CryptoEli Lilly reports 50% pediatric ulcerative colitis remission
United StatesEli Lilly reports 27.7 percent Omvoh remission rate
United StatesLilly reports broader biomarker changes with combination
United States
Dividend history
Dividends per share paid by Eli Lilly and Company, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $6.9200 |
| FY2025 | — | — | — | $6.0000 |
| FY2024 | — | — | — | $5.2000 |
| FY2023 | — | — | — | $4.5200 |
| FY2022 | — | — | — | $3.9200 |
Key financials
Reported results for Eli Lilly and Company, in USD.
- Market cap
- 1.3T
- Revenue (TTM)
- 86.5B
- P/E ratio
- 46.0
- EPS (diluted, TTM)
- 30.7
- Dividend yield
- 0.5%
- Profit margin
- 31.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 65.2B | 29.7B | 20.6B | |
| 45B | 17B | 10.6B | |
| 34.1B | 10.8B | 5.2B | |
| 28.5B | 8.7B | 6.2B |